International journal of gastrointestinal cancer最新文献

{"title":"Clinicopathological comparison between young and old age patients with gastric adenocarcinoma.","authors":"Kamal E Bani-Hani","doi":"10.1385/IJGC:35:1:043","DOIUrl":"https://doi.org/10.1385/IJGC:35:1:043","url":null,"abstract":"<p><strong>Background: </strong>There are controversies regarding the differences in the clinicopathological characteristics of gastric cancer between young and older patients. Our aim was to establish clinicopathological differences between both groups.</p><p><strong>Patients and methods: </strong>Records of all Jordanian patients with gastric adenocarcinoma managed at our hospitals between 1991 and 2001 were reviewed. Patients were divided into two groups according to their age; young patients (<or=40 yr of age; n=17), and older patients (>40 yr of age; n=159). The clinicopathological features and overall survival data for both groups were retrospectively analyzed and compared.</p><p><strong>Results: </strong>In the young group, in comparison with older group, females were more predominant (p=0.049), family history of gastric cancer was more common (p=0.006), proximal location and involvement of the entire stomach were more (p<0.001), and diffuse cancers (65% vs 13%) and poorly differentiated carcinomas (47% vs 26%) were more prevalent. Advanced tumor stage was the same in both groups (65% vs 64%, ns). There was no significant difference in survival between young and old patients (p=0.287). However, age was significantly associated with survival when treated as a continuous variable even after adjusting for the effects of site and stage of tumor on survival. The probability of death was increased by 5.6% with each yr of age.</p><p><strong>Conclusions: </strong>Special features of gastric cancer differ significantly between young and older age groups. Greater awareness of early-onset gastric cancer is mandatory for detecting cancer early enough so that it is treated successfully.</p>","PeriodicalId":84927,"journal":{"name":"International journal of gastrointestinal cancer","volume":"35 1","pages":"43-52"},"PeriodicalIF":0.0,"publicationDate":"2005-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1385/IJGC:35:1:043","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25136186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary minute invasive de novo colonic adenocarcinoma appearing as submucosal tumor.","authors":"Takahiro Zenda,&nbsp;Takaharu Masunaga,&nbsp;Kimihide Shinozaki,&nbsp;Atsushi Hashiba,&nbsp;Bungo Fuwa,&nbsp;Toshihide Okada,&nbsp;Toshinari Minamoto,&nbsp;Hiroshi Minato","doi":"10.1385/IJGC:36:3:177","DOIUrl":"https://doi.org/10.1385/IJGC:36:3:177","url":null,"abstract":"<p><p>A 4 mm white-yellow submucosal tumor-like lesion was detected in the sigmoid colon of an asymptomatic 52-yr-old Japanese man. Because the lesion was unexpectedly suspicious for adenocarcinoma by pathological examination of the biopsy specimen, it was treated by endoscopic mucosal resection. The specimen obtained demonstrated well-differentiated adenocarcinoma without any adenomatous element, and was located principally in the submucosal layer with a maximum depth of 1600 mum from the muscularis mucosae. The cancer exposed to the luminal surface was pathologically concluded to be diminutive. Intriguingly, aggregation of lymphocytes was found beneath the mucosal layer, which might have compromised the integrity of the muscularis mucosae. Because of deep submucosal infiltration and the latent aggressive nature of de novo cancer, the patient underwent an additional partial sigmoidcolectomy, which demonstrated no residual cancer and no regional lymph node metastasis. The lesion in this patient exhibited a previously undescribed appearance of de novo colon cancer as submucosal tumor in an early phase of growth.</p>","PeriodicalId":84927,"journal":{"name":"International journal of gastrointestinal cancer","volume":"36 3","pages":"177-81"},"PeriodicalIF":0.0,"publicationDate":"2005-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1385/IJGC:36:3:177","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26041862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of primary gastric small cell carcinoma with a rare pattern of lymph node metastasis.","authors":"Hiroya Takeuchi,&nbsp;Ken Futamata,&nbsp;Arafumi Maeshima,&nbsp;Shigemichi Hirose,&nbsp;Atsushi Shimada,&nbsp;Yoshiki Kawaguchi,&nbsp;Jo Tokuyama,&nbsp;Koji Osumi,&nbsp;Shinya Kishi,&nbsp;Takashi Hojo,&nbsp;Shiei Kim,&nbsp;Norihito Wada,&nbsp;Takashi Oishi,&nbsp;Yoh Isobe,&nbsp;Shunji Ikeuchi,&nbsp;Kiyoshi Kubochi,&nbsp;Sumio Matsumoto","doi":"10.1385/IJGC:36:2:99","DOIUrl":"https://doi.org/10.1385/IJGC:36:2:99","url":null,"abstract":"<p><p>We report a very rare case of primary gastric small cell carcinoma (GSCC) that was accompanied with gastric tubular adenocarcinoma. A male in his 60s had an elevated tumor with a central ulceration in the middle stomach. The patient underwent a distal gastrectomy with lymph node dissection. The pathological examination showed two separated lesions of the stomach, which contained the components of primary GSCC and primary gastric tubular adenocarcinoma. Immunohistochemical (IHC) examination demonstrated that the tumor cells in the small cell carcinoma stained positive for synaptophysin, chromogranin A, and neural cell adhesion molecule (NCAM). GSCC cells and adenocarcinoma cells independently metastasized to each regional lymph node. Further studies on the biological behavior of individual tumors may allow the development of new treatment strategies for GSCC.</p>","PeriodicalId":84927,"journal":{"name":"International journal of gastrointestinal cancer","volume":"36 2","pages":"99-104"},"PeriodicalIF":0.0,"publicationDate":"2005-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1385/IJGC:36:2:99","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26437203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Doxorubicin and streptozotocin after failed biotherapy of neuroendocrine tumors.","authors":"Marianne E Pavel,&nbsp;Ulrich Baum,&nbsp;Eckhart G Hahn,&nbsp;Johannes Hensen","doi":"10.1385/IJGC:35:3:179","DOIUrl":"https://doi.org/10.1385/IJGC:35:3:179","url":null,"abstract":"<p><strong>Background: </strong>Well-differentiated neuroendocrine tumors are treated primarily with somatostatin analogs and interferon-alpha. It is not clear what therapy should be applied after failed biotherapy. Our aim was to establish whether patients whose tumors rapidly progress under biotherapy may benefit from chemotherapy.</p><p><strong>Patients and methods: </strong>In 10 patients with metastatic neuroendocrine tumors (4 foregut, 3 midgut, 1 retroperitoneal, and 2 of unknown origin) streptozotocin and doxorubicin were used as second-line or third-line therapy. Tumor response was assessed by computed tomography of the abdomen and thorax and measurement of tumor secretion products (serum chromogranin A, urinary 5-hydroxyindoleacetic acid).</p><p><strong>Results: </strong>Three patients showed a radiological response over a mean time of 30 mo (range: 7-67 mo). Median survival after initiation of chemotherapy was 50 mo in patients with a response and 8 mo in non-responders. Three patients developed major side effects (nephrotoxicity, diabetes, and encephalopathy).</p><p><strong>Conclusion: </strong>Streptozotocin and doxorubicin produce poor response rates in patients with progressive neuroendocrine tumors after failed biotherapy, but may prolong life in those patients who show a tumor response.</p>","PeriodicalId":84927,"journal":{"name":"International journal of gastrointestinal cancer","volume":"35 3","pages":"179-85"},"PeriodicalIF":0.0,"publicationDate":"2005-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1385/IJGC:35:3:179","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25257634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential role of flavonoids in the prevention of intestinal neoplasia: a review of their mode of action and their clinical perspectives.","authors":"Harald P Hoensch,&nbsp;Wilhelm Kirch","doi":"10.1385/IJGC:35:3:187","DOIUrl":"https://doi.org/10.1385/IJGC:35:3:187","url":null,"abstract":"<p><p>Intestinal neoplasia (adenomas and carcinomas) can possibly be prevented by a diet rich in vegetables and fruits, treatment with aspirin and other nonsteroidal antiinflammatory drugs, and early colonoscopic removal of adenomas. Ballast, fiber, and secondary plant products could play a major role in colon cancer prevention. Recently there has been much experimental work in vitro and in vivo about flavonoids as inducers of bioprevention. Flavonoids are secondary plant products with a wide variety of beneficial biological properties, and they possess anticarcinogenic, antimutagenic, and antioxidative modes of actions. Flavonoids are the main components of a healthy diet containing fruits and vegetables and are concentrated especially in tea, apples, and onions. We will focus this review on flavonoids which are derived from tea products such as proanthocyanidins (green tea) and flavons (camomille tea). Oral supplementation with bioflavonoids derived from tea could be used in humans to prevent growth of intestinal neoplasia such as adenomatous polyps of the colon. Flavonoids are a large group of natural compounds of which only a few have been used in animal models, cell cultures, and enzyme studies to inhibit mutagenic and carcinogenic events. Their clinical mode of action was evaluated by epidemiological studies, but no intervention studies in humans have been performed so far. In vitro flavonoids can bind electrophils, inactivate oxygen radicals, prevent lipid peroxidation, and inhibit DNA oxidation. In cell cultures they increase the rate of apoptosis, inhibit cell proliferation, and angiogenesis. In vivo they can induce the activities of protective enzymes (conjugating enzymes such as glutathione transferases and glucuronosyl transferases) of the intestine and the liver. In models of intestinal polyposis, flavonoids suppress polyp formation. Some epidemiological studies show a protective effect of flavonoids contained in fruits, vegetables, and tea. Flavonoid mixtures of tea origin supplied as nutritional supplements could be studied as a new way of bioprevention of intestinal neoplasia (colon adenomas and cancer). Therefore, a controlled, randomized clinical study should be performed to evaluate the efficacy of flavonoids.</p>","PeriodicalId":84927,"journal":{"name":"International journal of gastrointestinal cancer","volume":"35 3","pages":"187-95"},"PeriodicalIF":0.0,"publicationDate":"2005-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1385/IJGC:35:3:187","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25257635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The outcome of laparoscopic gastrojejunostomy in malignant gastric outlet obstruction.","authors":"Simon M Denley,&nbsp;Susan J Moug,&nbsp;Christopher R Carter,&nbsp;Colin J McKay","doi":"10.1385/IJGC:35:3:165","DOIUrl":"https://doi.org/10.1385/IJGC:35:3:165","url":null,"abstract":"<p><strong>Background and aims: </strong>The development of gastric outlet obstruction (GOO) in patients with advanced pancreatic cancer is regarded by some as a terminal event. There are several interventional options available, one of which is laparoscopic gastrojejunostomy (LGJ). To date, there are little data on the effectiveness of this intervention. Using patient records we sought to analyze our own experience of LGJ in patients with terminal pancreatic cancer.</p><p><strong>Methods: </strong>A retrospective analysis of all patients with pancreatic or peri-ampullary cancer that underwent LGJ for GOO. All LGJ were performed by two consultant surgeons at Glasgow Royal Infirmary. Patient notes were assessed for survival time after LGJ; post-operative complications; resumption of oral intake; time to discharge and recurrence of GOO after surgery.</p><p><strong>Results: </strong>A total of 18 patients underwent LGJ for GOO between 2000 and 2004. Median age at time of procedure was 66.5 yr (range 40 to 79). Two patients were converted to an open procedure for technical reasons, both of whom died in the post-operative period. Of the remaining 16, 15 had successful relief of GOO. The remaining patient underwent revisional open surgery 15 d post-operatively due to persistent GOO. Two patients died in hospital but 14 were discharged with symptom relief. Median survival for these patients was 59 d (range 12 to 248).</p><p><strong>Conclusion: </strong>The development of GOO in pancreatic and peri-ampullary cancer should not be regarded as a terminal event. LGJ should be considered as a treatment option in these patients.</p>","PeriodicalId":84927,"journal":{"name":"International journal of gastrointestinal cancer","volume":"35 3","pages":"165-9"},"PeriodicalIF":0.0,"publicationDate":"2005-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1385/IJGC:35:3:165","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25257632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression of intestinal trefoil factor (TFF-3) in hepatocellular carcinoma.","authors":"Thaer Khoury,&nbsp;Krishdeep Chadha,&nbsp;Milind Javle,&nbsp;Kathleen Donohue,&nbsp;Charles Levea,&nbsp;Renuka Iyer,&nbsp;Haruhiko Okada,&nbsp;Hiroki Nagase,&nbsp;Dongfeng Tan","doi":"10.1385/IJGC:35:3:171","DOIUrl":"https://doi.org/10.1385/IJGC:35:3:171","url":null,"abstract":"<p><strong>Background: </strong>Trefoil peptides (TFF-1, 2, 3) are a family of protease-resistant regulatory factors that play a role in mucosal restitution, angiogenesis, apoptosis, and tumor progression. Intestinal trefoil peptide (TFF-3) expression has been demonstrated in benign hepatobiliary diseases, but there are limited data regarding its expression in HCC.</p><p><strong>Methods: </strong>Thirty consecutive cases of HCC from 1998 to 2003 were studied. Immunohistochemistry was performed on formalin-fixed paraffin-embedded blocks of HCC using polyclonal antibody to TFF-3. TFF-3 expression was classified as strong, moderate, weak, focal, and negative. Clinical data were obtained per an IRB-approved protocol.</p><p><strong>Results: </strong>Median age was 69 yr (range: 39-83 yr). Twenty- three patients were males and 7 were females. Treatments included hepatic resection (n = 16), chemo-embolization (n = 4), combined modality therapy (n = 5) and no treatment (n = 4). HCC was well differentiated in 12 (40%), moderately differentiated in 13 (43%), and poorly differentiated in 5 (17%) patients. TFF-3 expression was detected in 28/30 (93.3%) patient samples. Sixteen patients (53%) had moderate and 1 (3%) patient had strong TFF-3 expression. Tumor/ normal tissue interface was assessable in 21 cases; 11 cases expressed TFF-3 at the interface. There was a strong correlation between tumor grade and TFF-3 expression, wherein poorly differentiated tumors had moderate/strong TFF-3 expression (p = 0.008). There was no correlation between TFF-3 expression and survival (p = 0.77). Furthermore, there was no correlation among age, disease stage, and survival.</p><p><strong>Conclusion: </strong>TFF-3 is commonly expressed in HCC and its expression correlates with tumor grade.</p>","PeriodicalId":84927,"journal":{"name":"International journal of gastrointestinal cancer","volume":"35 3","pages":"171-7"},"PeriodicalIF":0.0,"publicationDate":"2005-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1385/IJGC:35:3:171","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25257633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"State of the art: gastrointestinal malignancies in the human immunodeficiency virus (HIV) population.","authors":"Mary Koshy,&nbsp;John Kauh,&nbsp;Clifford Gunthel,&nbsp;Melissa Joyner,&nbsp;Jerome Landry,&nbsp;Charles R Thomas","doi":"10.1385/IJGC:36:1:001","DOIUrl":"https://doi.org/10.1385/IJGC:36:1:001","url":null,"abstract":"<p><p>The gastrointestinal tract is one of the most common sites for the development of primary neoplasms arising in patients with pre-existing infection with the human immunodeficiency virus (HIV). Over the past decade, new information on the clinical manifestation, natural history, treatment options, and related toxicity have been reported, mostly notably the integration of highly active antiretroviral therapy (HAART). The following is a concise review summarizing the current state-of-the-art for GI tract malignancies in the HIV-positive patient and is designed to assist the clinical oncology team in developing a rationale plan when caring for these patients.</p>","PeriodicalId":84927,"journal":{"name":"International journal of gastrointestinal cancer","volume":"36 1","pages":"1-14"},"PeriodicalIF":0.0,"publicationDate":"2005-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1385/IJGC:36:1:001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25637840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bowel obstruction in patients with metastatic cancer: does intervention influence outcome?","authors":"Colette R Pameijer,&nbsp;David M Mahvi,&nbsp;James A Stewart,&nbsp;Sharon M Weber","doi":"10.1385/IJGC:35:2:127","DOIUrl":"https://doi.org/10.1385/IJGC:35:2:127","url":null,"abstract":"<p><strong>Background: </strong>Both surgical and nonsurgical options are available to treat bowel obstruction in patients with metastatic cancer. The goal is straightforward: to restore bowel patency and palliate the symptoms of obstruction. Yet the most appropriate management is often a challenging decision.</p><p><strong>Aim of the study: </strong>We sought to review our experience in managing patients with metastatic cancer and bowel obstruction.</p><p><strong>Methods: </strong>A retrospective review was performed to identify all patients admitted at University of Wisconsin Hospital between 1993 and 2000 with the diagnoses of both bowel obstruction and metastatic cancer. Demographic data, type of management, postoperative complications, and outcome were analyzed.</p><p><strong>Results: </strong>A total of 114 patients with primarily colorectal or gynecologic malignancies were identified. Patients' first bowel obstructions were managed in one of two ways: (1) definitive surgical intervention (n = 47), or (2) conservative management (n = 67). The median overall survival was 3 mo for the entire study group. There was no significant difference in overall or obstruction-free survival based on management, presence of recurrent bowel obstruction, or type of primary cancer. The only factor that was significant in predicting poor overall survival included a disease-free interval of less than 1 yr (time of diagnosis of primary cancer to time of bowel obstruction, p = 0.002).</p><p><strong>Conclusions: </strong>Bowel obstruction in patients with metastatic cancer is a terminal event, with a 3-mo median survival. Because there is no difference in overall or obstruction-free survival based on management, the treatment for palliation of bowel obstruction in patients with metastatic cancer should be individualized.</p>","PeriodicalId":84927,"journal":{"name":"International journal of gastrointestinal cancer","volume":"35 2","pages":"127-33"},"PeriodicalIF":0.0,"publicationDate":"2005-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1385/IJGC:35:2:127","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25098103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gallbladder carcinoma presenting as exfoliative dermatitis (erythroderma).","authors":"Hitoshi Kameyama,&nbsp;Yoshio Shirai,&nbsp;Kazutoshi Date,&nbsp;Akifumi Kuwabara,&nbsp;Ryo Kurosaki,&nbsp;Katsuyoshi Hatakeyama","doi":"10.1385/IJGC:35:2:153","DOIUrl":"https://doi.org/10.1385/IJGC:35:2:153","url":null,"abstract":"<p><p>Although exfoliative dermatitis (erythroderma) secondary to malignancy is commonly associated with lymphomas or leukemias, coincident gastrointestinal (GI) malignancy and erythroderma is rare. The authors recently encountered a patient with gallbladder carcinoma presenting as erythroderma. A 77-yr-old Japanese man presented with a 3-mo history of erythematous eruptions with pruritus over almost the entire body. After confirming the diagnosis of erythroderma, asymptomatic gallbladder carcinoma was found. Further investigations detected no malignancies in other organs. An extended cholecystectomy was performed. Histologic examination of resected specimens revealed poorly differentiated adenocarcinoma with negative resection margins. The eruptions with pruritus resolved within 1 wk after the operation. This is the first report, to our knowledge, of coincident biliary malignancy and erythroderma. The experience of the current patient suggests that erythroderma secondary to GI malignancy may resolve spontaneously after curative resection of the tumor.</p>","PeriodicalId":84927,"journal":{"name":"International journal of gastrointestinal cancer","volume":"35 2","pages":"153-5"},"PeriodicalIF":0.0,"publicationDate":"2005-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1385/IJGC:35:2:153","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25098107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}